About

Joseph (Joe) Vazzano joined Abeona as Chief Financial Officer in March 2022. Before joining Abeona, he served as Chief Financial Officer of Avenue Therapeutics, Inc. (Nasdaq: ATXI) from February 2019 to January 2022, and previously as Avenue's Vice President of Finance and Corporate Controller from August 2017, where he secured multiple equity financings and served in a leadership role on a complex, two-stage acquisition with future contingent value rights. Earlier he was Assistant Corporate Controller at Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) from October 2016 to July 2017, helping grow the finance and accounting department during the company's transition from a development-stage company to a fully integrated commercial organization.

Roles

Abeona Therapeutics Inc.
Chief Financial Officer · Current role
March 2022–present
Abeona Therapeutics Inc.
Chief Financial Officer
March 2022 - present
Avenue Therapeutics, Inc. (Nasdaq: ATXI)
Chief Financial Officer
February 2019 - January 2022
Avenue Therapeutics, Inc.
Vice President of Finance and Corporate Controller
August 2017 - February 2019
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT)
Assistant Corporate Controller
October 2016 - July 2017

Fixed Compensation

FY 2025
Salary
$475,903
ComponentAnnual base salary earned in FY2025
Bonus
$235,333
ComponentCash retention bonus paid June 23, 2025 to offset a 2022 equity shortfall versus recommended market grant
All other compensation
$14,000
ComponentEmployer matching contributions to the 401(k) Defined Contribution Plan
Total compensation
$1,734,865

Performance Compensation

Data from FY 2025

Cash incentive

Non-equity incentive plan compensation
$173,229
Target Opportunity
PlanTarget-based cash incentive bonus earned with respect to FY2025

Stock awards

Stock awards
$836,400
FormRestricted stock awards, aggregate grant-date fair value computed in accordance with ASC 718

Also at Abeona Therapeutics Inc.

Related

See how VectorShift works for your firm

Request Demo